BioCryst Pharmaceuticals announces restructuring

BioCryst is streamlining its portfolio of antivirals in a bid to lower costs.

A bio pharma company has announced restructuring that will see it focus efforts on its antiviral programmes, following an assessment of all of its assets.

Based in Alabama, BioCryst Pharmaceuticals aims to significantly reduce its costs as part of the restructuring, as well as the scale of its organisation in line with a new streamlined portfolio.

The company will focus on advancing its hereditary angiodema programme, alongside its BCX4161 HAE and BCX4430 broad spectrum antivirals, and its BCX5191 hepatitis C treatment.

Jon Stonehouse, president and chief executive of BioCryst, said: "The strategic focus and restructuring announced today is based on an evaluation of our programmes and operations, following the setbacks in our peramivir and BCX5191 programmes, as well as the delay in our BCX4161 programme.

"The restructuring is a necessary but difficult measure that impacts many talented and dedicated BioCryst employees who will be leaving the company," he added. "We are grateful for their meaningful contributions and commitment over the years.

The compmany is currently conducting a study into the efficacy of low doses of BCX5191 in the treatment of the hepatitis C virus.